BioInvent International AB - Asset Resilience Ratio
BioInvent International AB (BINV) has an Asset Resilience Ratio of 42.92% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is BioInvent International AB's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2024)
This chart shows how BioInvent International AB's Asset Resilience Ratio has changed over time. See BioInvent International AB (BINV) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down BioInvent International AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BINV company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr393.47 Million | 42.92% |
| Total Liquid Assets | Skr393.47 Million | 42.92% |
Asset Resilience Insights
- Very High Liquidity: BioInvent International AB maintains exceptional liquid asset reserves at 42.92% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
BioInvent International AB Industry Peers by Asset Resilience Ratio
Compare BioInvent International AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 2.21% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
ABL Bio Inc
KQ:298380 |
Biotechnology | 1.05% |
|
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP |
Biotechnology | 80.13% |
|
Ascletis Pharma Inc
F:2VJ |
Biotechnology | 22.13% |
|
ABCELLERA BIOLOGICS
F:8QQ |
Biotechnology | 29.87% |
Annual Asset Resilience Ratio for BioInvent International AB (2000–2024)
The table below shows the annual Asset Resilience Ratio data for BioInvent International AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 43.70% | Skr432.33 Million ≈ $46.53 Million |
Skr989.24 Million ≈ $106.46 Million |
-14.09pp |
| 2023-12-31 | 57.79% | Skr809.15 Million ≈ $87.08 Million |
Skr1.40 Billion ≈ $150.68 Million |
+28.44pp |
| 2022-12-31 | 29.34% | Skr502.43 Million ≈ $54.07 Million |
Skr1.71 Billion ≈ $184.26 Million |
+17.45pp |
| 2021-12-31 | 11.89% | Skr172.07 Million ≈ $18.52 Million |
Skr1.45 Billion ≈ $155.75 Million |
-5.79pp |
| 2017-12-31 | 17.68% | Skr30.06 Million ≈ $3.23 Million |
Skr170.05 Million ≈ $18.30 Million |
-32.29pp |
| 2014-12-31 | 49.97% | Skr37.03 Million ≈ $3.98 Million |
Skr74.11 Million ≈ $7.98 Million |
-11.52pp |
| 2013-12-31 | 61.49% | Skr50.07 Million ≈ $5.39 Million |
Skr81.44 Million ≈ $8.76 Million |
-6.59pp |
| 2012-12-31 | 68.07% | Skr79.34 Million ≈ $8.54 Million |
Skr116.54 Million ≈ $12.54 Million |
+28.41pp |
| 2011-12-31 | 39.67% | Skr81.62 Million ≈ $8.78 Million |
Skr205.76 Million ≈ $22.14 Million |
-10.41pp |
| 2010-12-31 | 50.07% | Skr69.12 Million ≈ $7.44 Million |
Skr138.03 Million ≈ $14.85 Million |
+42.17pp |
| 2009-12-31 | 7.91% | Skr9.98 Million ≈ $1.07 Million |
Skr126.25 Million ≈ $13.59 Million |
-46.65pp |
| 2008-12-31 | 54.56% | Skr161.18 Million ≈ $17.35 Million |
Skr295.43 Million ≈ $31.79 Million |
-2.40pp |
| 2007-12-31 | 56.96% | Skr154.37 Million ≈ $16.61 Million |
Skr271.00 Million ≈ $29.16 Million |
+43.51pp |
| 2006-12-31 | 13.45% | Skr19.96 Million ≈ $2.15 Million |
Skr148.33 Million ≈ $15.96 Million |
-8.99pp |
| 2005-12-31 | 22.45% | Skr59.78 Million ≈ $6.43 Million |
Skr266.34 Million ≈ $28.66 Million |
+17.18pp |
| 2000-12-31 | 5.27% | Skr10.23 Million ≈ $1.10 Million |
Skr194.26 Million ≈ $20.91 Million |
-- |
About BioInvent International AB
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and a type of blood cancer; BI-1206, an a… Read more